Table 6.
Ongoing clinical trials of PARP-targeted therapy in UC
| Drugs | Targets | Combinations | Conditions | Phase | NCT |
|---|---|---|---|---|---|
| Niraparib | PARP | Dostarlimab | UC | II | NCT04779151 |
| Niraparib | PARP | Atezolizumab | UC | I/II | NCT03869190 |
| Olaparib | PARP | Null | Met/Adv UC | II | NCT03375307 |
| Olaparib | PARP | EP0057 | UC | I/II | NCT02769962 |
| Olaparib | PARP | Durvalumab | UC | MIBC | I | NCT02546661 |
| Olaparib | PARP | Ceralasertib | Met UC | II | NCT03682289 |
| Talazoparib | PARP | Avelumab | UC | II | NCT04678362 |
| Veliparib | PARP | Paclitaxel, carboplatin | UC | I | NCT01366144 |
Null in combination indicates that the trial is monotherapy. PARP: poly ADP-ribose polymerase; MIBC: muscle-invasive bladder cancer; UC: urothelial carcinoma; Adv: advanced; Met: metastatic. |: and